Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 5/20 | 0.54 |
| ▸ | MEN1 | O00255 | 5/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.46 |
| ▸ | ALPL | P05186 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7339887 | 0.94 | TSHR (0.73) | TSHRMAPTMEN1KMT2ARAB9A | |
| SCHEMBL1026971 | 0.88 | TSHR (0.62) | TSHRMAPTMEN1KMT2ARAB9A | |
| SCHEMBL11247732 | 0.88 | CASP6 (0.57) | TSHRMAPTKMT2ARAB9ANPC1 | |
| SCHEMBL7717398 | 0.86 | TSHR (0.50) | TSHRMAPTMEN1KMT2ARAB9A | |
| SCHEMBL7336807 | 0.86 | TSHR (0.50) | TSHRMAPTMEN1KMT2ARAB9A | |
| SCHEMBL25484994 | 0.85 | GPR35 (0.47) | TSHRMAPTLMNAALDH1A1VCAM1 | |
| SCHEMBL557153 | 0.85 | VCAM1 (0.46) | TSHRMAPTMEN1KMT2ARAB9A | |
| SCHEMBL357203 | 0.84 | ATM (0.47) | TSHRMAPTMEN1KMT2ARAB9A | |
| SCHEMBL15292815 | 0.84 | VCAM1 (0.45) | TSHRMAPTMEN1KMT2ARAB9A | |
| SCHEMBL29966142 | 0.84 | ATM (0.47) | TSHRMAPTMEN1KMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513235-B2 | Homocysteine synthase inhibitor | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-08-20 | — | — | US | disclosed |
| EP-2486925-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | Mitsubishi Tanabe Pharma Corporation (JP) | 2012-08-15 | — | — | EP | disclosed |
| US-20120196824-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-08-02 | — | — | US | disclosed |
| US-20110034440-A1 | HOMOCYSTEINE SYNTHASE INHIBITOR | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-02-10 | — | — | US | disclosed |
| EP-2275404-A1 | HOMOCYSTEINE SYNTHASE INHIBITOR | Mitsubishi Tanabe Pharma Corporation (JP) | 2011-01-19 | — | — | EP | disclosed |
| EP-1225895-B1 | FAB I INHIBITORS | AFFINIUM PHARM INC (CA) | 2005-05-04 | — | — | EP | disclosed |
| WO-1995018619-A9 | BICYCLIC FIBRINOGEN ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2004-10-21 | — | — | WO | disclosed |
| US-6762201-B1 | SUCH AS N-((2-AMINO-5-(N-METHYL-N-((1-METHYLINDOL-2-YL) -METHYL)CARBAMOYL)PHENYL)METHYL)-N-METHYLACETAMIDE; BACTERIAL INFECTIONS | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2004-07-13 | — | — | US | disclosed |
| EP-0946180-A4 | METHOD FOR STIMULATING BONE FORMATION | SMITHKLINE BEECHAM CORP (US) | 2003-07-23 | — | — | EP | disclosed |
| EP-0738150-B1 | BICYCLIC FIBRINOGEN ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2003-05-02 | — | — | EP | disclosed |
| US-5939412-A | Bicyclic fibrinogen antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1999-08-17 | — | — | US | disclosed |
| EP-0869787-A4 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 1999-03-24 | — | — | EP | disclosed |
| EP-0869787-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-10-14 | — | — | EP | disclosed |
| WO-1998015278-A1 | METHOD FOR STIMULATING BONE FORMATION | SMITHKLINE BEECHAM CORPORATION (US) | 1998-04-16 | — | — | WO | disclosed |
| US-5693636-A | Bicyclic fibrinogen antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1997-12-02 | — | — | US | disclosed |
| WO-1997024119-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-07-10 | — | — | WO | disclosed |
| EP-0767792-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-04-16 | — | — | EP | disclosed |
| WO-1996000730-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1996-01-11 | — | — | WO | disclosed |
| EP-0593603-A1 | BICYCLIC FIBRINOGEN ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-04-27 | — | — | EP | disclosed |
| WO-1993000095-A2 | BICYCLIC FIBRINOGEN ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196824-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | FABP7, TIMP3, MMP11 | TSHR 4241/4885MAPT 230/4885MEN1 2301/4885 |
| US-20110034440-A1 | HOMOCYSTEINE SYNTHASE INHIBITOR | BHMT, CBS, BHMT2 | TSHR 2667/4885MAPT 1767/4885MEN1 514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.